[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol]
Author(s): Xiang DR, Sheng JF
Affiliation(s): Zhejiang University First Hospital, Hangzhou 310003, China.
Publication date & source: 2009-08, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi., 23(4):299-301.
Publication type: English Abstract; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
OBJECTIVE: To analyze the efficacy of adefovir dipivoxil combined with bicyclol in treatment of HBeAg-positive chronic viral hepatitis B (CHB). METHODS: A total of 91 patients with CHB were randomized into experimental group and control group to be treated. The patients in experimental group (46 samples) received adefovir dipivoxil orally 10 mg daily and bicyclol orally 150 mg daily for 48 weeks and those in control group (45 samples) received adefovir dipivoxil orally 10 mg daily alone for 48 weeks. The serum aminotransferace (ALT/ AST), HBV-DNA, HBeAg/antiHBe were observed before and after treatment. RESULTS: Compared with pretreatment, the serum aminotransferace were all decreased obviously in two groups, the experimental group is better (P < 0.05). HBVDNA negative conversion rate was significantly higher in experimental group than in the control group (47.8% vs. 31.1%, P < 0.05). There were nostatistically differrence between the two groups in the portion of HBeAg loss rate and HBeAg seroconversion rate. There were no obvious adverse reaction in the study. CONCLUSION: Adefovir dipivoxil combined with bicyclol is efective in the treatment of chronic hepatitis B.